Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Technical advance

Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX®Colon Cancer Assay

Authors: Kim M Clark-Langone, Chithra Sangli, Jayadevi Krishnakumar, Drew Watson

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

The Oncotype DX® Colon Cancer Assay is a new diagnostic test for determining the likelihood of recurrence in stage II colon cancer patients after surgical resection using fixed paraffin embedded (FPE) primary colon tumor tissue. Like the Oncotype DX Breast Cancer Assay, this is a high complexity, multi-analyte, reverse transcription (RT) polymerase chain reaction (PCR) assay that measures the expression levels of specific cancer-related genes. By capturing the biology underlying each patient's tumor, the Oncotype DX Colon Cancer Assay provides a Recurrence Score (RS) that reflects an individualized risk of disease recurrence. Here we describe its analytical performance using pre-determined performance criteria, which is a critical component of molecular diagnostic test validation.

Results

All analytical measurements met pre-specified performance criteria. PCR amplification efficiency for all 12 assays was high, ranging from 96% to 107%, while linearity was demonstrated over an 11 log2 concentration range for all assays. Based on estimated components of variance for FPE RNA pools, analytical reproducibility and precision demonstrated low SDs for individual genes (0.16 to 0.32 CTs), gene groups (≤0.05 normalized/aggregate CTs) and RS (≤1.38 RS units).

Conclusions

Analytical performance characteristics shown here for both individual genes and gene groups in the Oncotype DX Colon Cancer Assay demonstrate consistent translation of specific biology of individual tumors into clinically useful diagnostic information. The results of these studies illustrate how the analytical capability of the Oncotype DX Colon Cancer Assay has enabled clinical validation of a test to determine individualized recurrence risk after colon cancer surgery.
Appendix
Available only for authorised users
Literature
1.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004, 351: 2817-2826. 10.1056/NEJMoa041588.CrossRefPubMed
2.
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE, Wickerham DL, Wolmark N: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006, 24: 3726-3734. 10.1200/JCO.2005.04.7985.CrossRefPubMed
3.
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007, 25: 5287-5312. 10.1200/JCO.2007.14.2364.CrossRefPubMed
4.
5.
Oratz R, Paul D, Cohn A, Sedlacek S: Impact of a commercial reference laboratory test Recurrence Score on decision making in ealry-stage breast cancer. J Oncol Practice. 2007, 3: 5287-5312.CrossRef
6.
O'Connell M, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, Cowens J, Wolmark N: Relationship between tumor gene expression and recurrence in four independant studies of stage II/II colon cancer patients treated with surgery alone and surgery plus 5-FU/LV. J Clin Oncol. 2010, 28: 3937-3944.CrossRefPubMedPubMedCentral
7.
Kerr D, Gray R, Quirke P, Watson D, Yothers G, Lavery I, Lee M, O'Connel MA: A quantitative multi-gene RT-qPCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in 4 large studies and results from the independent, prospectively-defined QUASAR calidation study. J Clin Oncol. 2009, 27: 15s-10.1200/JCO.2008.21.7695.CrossRef
8.
Clark-Langone KM, Wu JY, Sangli C, Chen A, Snable JL, Nguyen A, Hackett JR, Baker J, Yothers G, Kim C, Cronin MT: Biomarker discovery for colon cancer using a 761 gene RT-PCR assay. BMC Genomics. 2007, 8: 279-10.1186/1471-2164-8-279.CrossRefPubMedPubMedCentral
9.
Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, Esteban JM, Baker JB: Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol. 2004, 164: 35-42.CrossRefPubMedPubMedCentral
10.
Krouwer JS, Schlain B: A method to quantify deviations from assay linearity. Clin Chem. 1993, 39: 1689-1693.PubMed
11.
Clinical Laboratory Standards Institute: Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline. CLSI document EP6-A. ISBN 1-56238-498-8
12.
13.
Cronin M, Sangli C, Liu M, Pho M, Dutta D, Nguyen A, Jeong J, Wu J, Langone KC, Watson D: Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem. 2007, 53: 1084-1091. 10.1373/clinchem.2006.076497.CrossRefPubMed
14.
Allanach K, Mengel M, Einecke G, Sis B, Hidalgo LG, Mueller T, Halloran PF: Comparing microarray versus RT-PCR assessment of renal allograft biopsies: similar performance despite different dynamic ranges. Am J Transplant. 2008, 8: 1006-1015. 10.1111/j.1600-6143.2008.02199.x.CrossRefPubMed
15.
Shippy R, Sendera TJ, Lockner R, Palaniappan C, Kaysser-Kranich T, Watts G, Alsobrook J: Performance evaluation of commercial short-oligonucleotide microarrays and the impact of noise in making cross-platform correlations. BMC Genomics. 2004, 5: 61-10.1186/1471-2164-5-61.CrossRefPubMedPubMedCentral
16.
Glas AM, Floore A, Delahaye LJMJ, Witteveen AT, Pover RCF, Bakx N, Lahti-Domenici JST, Bruinsma TJ, Warmoes MO, Bernards R, Wessels LFA, van't Veer LJ: Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics. 2006, 7: 278-10.1186/1471-2164-7-278.CrossRefPubMedPubMedCentral
17.
Ach RA, Floore A, Curry B, Lazar V, Glas AM, Pover R, Tsalenko A, Ripoche H, Cardoso F, d'Assignies MS, Bruhn L, van't Veer LJ: Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools. BMC Genomics. 2007, 8: 148-10.1186/1471-2164-8-148.CrossRefPubMedPubMedCentral
18.
Shi L, et al: The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol. 2006, 24: 1151-1161. 10.1038/nbt1239.CrossRefPubMed
19.
Shi L, et al: The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies. BMC Bioinformatics. 2008, 9 (Suppl 9): S10-10.1186/1471-2105-9-S9-S10.CrossRefPubMedPubMedCentral
20.
Sato F, Tsuchiya S, Terasawa K, Tsujimoto G: Intra-platform repeatability and inter-platform comparability of microRNA microarray technology. PLoS ONE. 2009, 4: e5540-10.1371/journal.pone.0005540.CrossRefPubMedPubMedCentral
21.
Dvorak HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986, 315: 1650-1659. 10.1056/NEJM198612253152606.CrossRefPubMed
22.
Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi J, van de Rijn M, Botstein D, Brown PO: Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004, 2: E7-10.1371/journal.pbio.0020007.CrossRefPubMedPubMedCentral
23.
24.
Sugiyama Y, Farrow B, Murillo C, Li J, Watanabe H, Sugiyama K, Evers BM: Analysis of differential gene expression patterns in colon cancer and cancer stroma using microdissected tissues. Gastroenterology. 2005, 128: 480-486. 10.1053/j.gastro.2004.11.010.CrossRefPubMed
25.
Chang HY, Nuyten DSA, Sneddon JB, Hastie T, Tibshirani R, Sørlie T, Dai H, He YD, van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, van de Vijver MJ: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA. 2005, 102: 3738-3743. 10.1073/pnas.0409462102.CrossRefPubMedPubMedCentral
26.
27.
Riss J, Khanna C, Koo S, Chandramouli GVR, Yang HH, Hu Y, Kleiner DE, Rosenwald A, Schaefer CF, Ben-Sasson SA, Yang L, Powell J, Kane DW, Star RA, Aprelikova O, Bauer K, Vasselli JR, Maranchie JK, Kohn KW, Buetow KH, Linehan WM, Weinstein JN, Lee MP, Klausner RD, Barrett JC: Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. Cancer Res. 2006, 66: 7216-7224. 10.1158/0008-5472.CAN-06-0040.CrossRefPubMed
28.
Mesker WE, Liefers G, Junggeburt JMC, van Pelt GW, Alberici P, Kuppen PJK, Miranda NF, van Leeuwen KAM, Morreau H, Szuhai K, Tollenaar RAEM, Tanke HJ: Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cell Oncol. 2009, 31: 169-178.PubMedPubMedCentral
29.
Mesker WE, Junggeburt JMC, Szuhai K, de Heer P, Morreau H, Tanke HJ, Tollenaar RAEM: The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol. 2007, 29: 387-398.PubMedPubMedCentral
30.
Ungefroren H, Groth S, Ruhnke M, Kalthoff H, Fändrich F: Transforming growth factor-beta (TGF-beta) type I receptor/ALK5-dependent activation of the GADD45beta gene mediates the induction of biglycan expression by TGF-beta. J Biol Chem. 2005, 280: 2644-2652. 10.1074/jbc.M411925200.CrossRefPubMed
31.
Anjomshoaa A, Lin Y, Black MA, McCall JL, Humar B, Song S, Fukuzawa R, Yoon H, Holzmann B, Friederichs J, van Rij A, Thompson-Fawcett M, Reeve AE: Reduced expression of a gene proliferation signature is associated with enhanced malignancy in colon cancer. Br J Cancer. 2008, 99: 966-973. 10.1038/sj.bjc.6604560.CrossRefPubMedPubMedCentral
32.
Garrity MM, Burgart LJ, Mahoney MR, Windschitl HE, Salim M, Wiesenfeld M, Krook JE, Michalak JC, Goldberg RM, O'Connell MJ, Furth AF, Sargent DJ, Murphy LM, Hill E, Riehle DL, Meyers CH, Witzig TE: Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol. 2004, 22: 1572-1582. 10.1200/JCO.2004.10.042.CrossRefPubMed
33.
Salminen E, Palmu S, Vahlberg T, Roberts P, Söderström K: Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer. World J Gastroenterol. 2005, 11: 3245-3249.CrossRefPubMedPubMedCentral
34.
Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N, Wieand HS: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol. 2003, 21: 241-250. 10.1200/JCO.2003.05.044.CrossRefPubMed
35.
Green RA, Kaplan KB: Chromosome instability in colorectal tumor cells is associated with defects in microtubule plus-end attachments caused by a dominant mutation in APC. J Cell Biol. 2003, 163: 949-961. 10.1083/jcb.200307070.CrossRefPubMedPubMedCentral
36.
Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell. 1996, 87: 159-170. 10.1016/S0092-8674(00)81333-1.CrossRefPubMed
37.
Rowan AJ, Lamlum H, Ilyas M, Wheeler J, Straub J, Papadopoulou A, Bicknell D, Bodmer WF, Tomlinson IP: APC mutations in sporadic colorectal tumors: A mutational "hotspot" and interdependence of the "two hits". Proc Natl Acad Sci USA. 2000, 97: 3352-3357. 10.1073/pnas.97.7.3352.CrossRefPubMedPubMedCentral
38.
Albuquerque C, Breukel C, van der Luijt R, Fidalgo P, Lage P, Slors FJM, Leitão CN, Fodde R, Smits R: The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. Hum Mol Genet. 2002, 11: 1549-1560. 10.1093/hmg/11.13.1549.CrossRefPubMed
39.
Su LK, Barnes CJ, Yao W, Qi Y, Lynch PM, Steinbach G: Inactivation of germline mutant APC alleles by attenuated somatic mutations: a molecular genetic mechanism for attenuated familial adenomatous polyposis. Am J Hum Genet. 2000, 67: 582-590. 10.1086/303058.CrossRefPubMedPubMedCentral
40.
Cheadle JP, Krawczak M, Thomas MW, Hodges AK, Al-Tassan N, Fleming N, Sampson JR: Different combinations of biallelic APC mutation confer different growth advantages in colorectal tumours. Cancer Res. 2002, 62: 363-366.PubMed
41.
Tighe A, Johnson VL, Taylor SS: Truncating APC mutations have dominant effects on proliferation, spindle checkpoint control, survival and chromosome stability. J Cell Sci. 2004, 117: 6339-6353. 10.1242/jcs.01556.CrossRefPubMed
42.
Dihlmann S, Gebert J, Siermann A, Herfarth C, von Knebel Doeberitz M: Dominant negative effect of the APC1309 mutation: a possible explanation for genotype-phenotype correlations in familial adenomatous polyposis. Cancer Res. 1999, 59: 1857-1860.PubMed
43.
Rubinfeld B, Albert I, Porfiri E, Munemitsu S, Polakis P: Loss of beta-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene. Cancer Res. 1997, 57: 4624-4630.PubMed
44.
Kaplan KB, Burds AA, Swedlow JR, Bekir SS, Sorger PK, Näthke IS: A role for the Adenomatous Polyposis Coli protein in chromosome segregation. Nat Cell Biol. 2001, 3: 429-432. 10.1038/35070123.CrossRefPubMed
45.
Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B: Mutations of mitotic checkpoint genes in human cancers. Nature. 1998, 392: 300-303. 10.1038/32688.CrossRefPubMed
46.
Tighe A, Johnson VL, Albertella M, Taylor SS: Aneuploid colon cancer cells have a robust spindle checkpoint. EMBO Rep. 2001, 2: 609-614. 10.1093/embo-reports/kve127.CrossRefPubMedPubMedCentral
47.
Zhang J, Neisa R, Mao Y: Oncogenic Adenomatous polyposis coli mutants impair the mitotic checkpoint through direct interaction with Mad2. Mol Biol Cell. 2009, 20: 2381-2388. 10.1091/mbc.E08-12-1206.CrossRefPubMedPubMedCentral
48.
Kops GJPL, Weaver BAA, Cleveland DW: On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 2005, 5: 773-785. 10.1038/nrc1714.CrossRefPubMed
49.
Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, Kinzler KW, Vogelstein B, Hamilton SR: Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med. 1994, 331: 213-221. 10.1056/NEJM199407283310401.CrossRefPubMed
50.
Choi S, Lee KJ, Bae Y, Min K, Kwon M, Kim K, Rhyu M: Genetic classification of colorectal cancer based on chromosomal loss and microsatellite instability predicts survival. Clin Cancer Res. 2002, 8: 2311-2322.PubMed
51.
Chang S, Lin J, Lin T, Liang W: Loss of heterozygosity: an independent prognostic factor of colorectal cancer. World J Gastroenterol. 2005, 11: 778-784.CrossRefPubMedPubMedCentral
52.
Sinicrope FA, Rego RL, Halling KC, Foster N, Sargent DJ, La Plant B, French AJ, Laurie JA, Goldberg RM, Thibodeau SN, Witzig TE: Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology. 2006, 131: 729-737. 10.1053/j.gastro.2006.06.005.CrossRefPubMed
Metadata
Title
Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX®Colon Cancer Assay
Authors
Kim M Clark-Langone
Chithra Sangli
Jayadevi Krishnakumar
Drew Watson
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-691

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue

Research article

Orphan receptor GPR110, an oncogene overexpressed in lung and prostate cancer

Research article

The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time

Research article

Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population

Research article

Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial

Research article

Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells

Research article

Gene expression analysis of cell death induction by Taurolidine in different malignant cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits